AbbVie Eyes Japan Oncology Growth As Humira Biosimilar Looms
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
You may also be interested in...
As Japanese pharma companies report quarterly results, the multi-faceted impact of the ongoing coronavirus pandemic on business operations has become clearer. The good news is that it’s been limited so far and the situation has been generally improving.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.